Abstract
New data from the phase III QUAZAR AML-001 trial confirm the benefits of maintenance therapy with oral azacitidine in acute myeloid leukemia regardless of patients' minimal residual disease status or the number of consolidation cycles prior to study enrollment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
